vs
Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
DYNEX CAPITAL INC is the larger business by last-quarter revenue ($43.5M vs $38.3M, roughly 1.1× ImmunityBio, Inc.). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs 407.0%).
Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
DX vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.5M | $38.3M |
| Net Profit | — | $-61.9M |
| Gross Margin | — | 99.0% |
| Operating Margin | — | -169.0% |
| Net Margin | — | -161.8% |
| Revenue YoY | 531.3% | 407.0% |
| Net Profit YoY | — | -4.7% |
| EPS (diluted) | $1.59 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.5M | $38.3M | ||
| Q3 25 | $30.6M | $32.1M | ||
| Q2 25 | $23.1M | $26.4M | ||
| Q1 25 | $17.1M | $16.5M | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | — | $6.1M | ||
| Q1 24 | $-3.2M | — | ||
| Q4 22 | $6.2M | — |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | $150.4M | $-67.3M | ||
| Q2 25 | $-13.6M | $-92.6M | ||
| Q1 25 | $-3.1M | $-129.6M | ||
| Q4 24 | — | $-59.2M | ||
| Q3 24 | — | $-85.7M | ||
| Q1 24 | $40.1M | — | ||
| Q4 22 | $43.3M | — |
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | — | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | — | -169.0% | ||
| Q3 25 | — | -173.5% | ||
| Q2 25 | — | -269.8% | ||
| Q1 25 | — | -390.1% | ||
| Q4 24 | — | -919.0% | ||
| Q3 24 | — | -1314.3% | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | — | -161.8% | ||
| Q3 25 | 491.3% | -209.8% | ||
| Q2 25 | -58.8% | -350.3% | ||
| Q1 25 | -18.0% | -784.9% | ||
| Q4 24 | — | -783.4% | ||
| Q3 24 | — | -1404.0% | ||
| Q1 24 | -1256.8% | — | ||
| Q4 22 | 697.2% | — |
| Q4 25 | $1.59 | $-0.06 | ||
| Q3 25 | $1.08 | $-0.07 | ||
| Q2 25 | $-0.14 | $-0.10 | ||
| Q1 25 | $-0.06 | $-0.15 | ||
| Q4 24 | — | $-0.08 | ||
| Q3 24 | — | $-0.14 | ||
| Q1 24 | $0.64 | — | ||
| Q4 22 | $0.44 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $531.0M | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.5B | $-500.5M |
| Total Assets | $17.3B | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $531.0M | $242.8M | ||
| Q3 25 | $491.0M | $257.8M | ||
| Q2 25 | $387.5M | $153.7M | ||
| Q1 25 | $327.4M | $61.6M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $130.4M | ||
| Q1 24 | $295.7M | — | ||
| Q4 22 | $332.0M | — |
| Q4 25 | $2.5B | $-500.5M | ||
| Q3 25 | $2.0B | $-524.3M | ||
| Q2 25 | $1.6B | $-570.7M | ||
| Q1 25 | $1.4B | $-591.4M | ||
| Q4 24 | — | $-489.1M | ||
| Q3 24 | — | $-745.1M | ||
| Q1 24 | $958.5M | — | ||
| Q4 22 | $901.3M | — |
| Q4 25 | $17.3B | $501.9M | ||
| Q3 25 | $14.2B | $519.0M | ||
| Q2 25 | $11.3B | $402.1M | ||
| Q1 25 | $9.0B | $303.8M | ||
| Q4 24 | — | $382.9M | ||
| Q3 24 | — | $364.6M | ||
| Q1 24 | $6.3B | — | ||
| Q4 22 | $3.6B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.8M | $-70.4M |
| Free Cash FlowOCF − Capex | — | $-71.3M |
| FCF MarginFCF / Revenue | — | -186.2% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.8M | $-70.4M | ||
| Q3 25 | $68.3M | $-68.9M | ||
| Q2 25 | $31.9M | $-79.7M | ||
| Q1 25 | $6.4M | $-85.9M | ||
| Q4 24 | — | $-85.1M | ||
| Q3 24 | — | $-98.8M | ||
| Q1 24 | $-17.1M | — | ||
| Q4 22 | $30.1M | — |
| Q4 25 | — | $-71.3M | ||
| Q3 25 | — | $-69.6M | ||
| Q2 25 | — | $-80.8M | ||
| Q1 25 | — | $-87.0M | ||
| Q4 24 | — | $-87.3M | ||
| Q3 24 | — | $-101.6M | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | — | -186.2% | ||
| Q3 25 | — | -217.2% | ||
| Q2 25 | — | -305.9% | ||
| Q1 25 | — | -526.9% | ||
| Q4 24 | — | -1155.4% | ||
| Q3 24 | — | -1663.2% | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 4.1% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 28.0% | ||
| Q3 24 | — | 45.7% | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | -0.43× | — | ||
| Q4 22 | 0.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
